Senseonics Holdings Inc (SENS) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Senseonics Holdings Inc (NYSEMKT:SENS) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

According to Zacks, “Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. “

Several other research analysts have also recently commented on SENS. Canaccord Genuity reiterated a buy rating and issued a $6.00 price target on shares of Senseonics Holdings in a research note on Wednesday, August 10th. Leerink Swann reiterated an outperform rating and issued a $6.00 price target (up previously from $4.50) on shares of Senseonics Holdings in a research note on Thursday, September 22nd. Finally, B. Riley started coverage on Senseonics Holdings in a research note on Monday, September 26th. They issued a buy rating and a $5.50 price target on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Senseonics Holdings currently has a consensus rating of Buy and an average price target of $5.25.

Senseonics Holdings (NYSEMKT:SENS) opened at 3.39 on Wednesday. Senseonics Holdings has a 52 week low of $2.53 and a 52 week high of $4.24. The firm has a 50 day moving average price of $3.82 and a 200 day moving average price of $3.61. The stock’s market capitalization is $316.59 million.

Senseonics Holdings (NYSEMKT:SENS) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. Equities research analysts predict that Senseonics Holdings will post ($0.49) earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP purchased a new stake in shares of Senseonics Holdings during the first quarter valued at about $13,460,000. BlackRock Fund Advisors bought a new position in Senseonics Holdings during the second quarter valued at approximately $2,812,000. Vanguard Group Inc. bought a new position in Senseonics Holdings during the second quarter valued at approximately $2,387,000. Abingworth LLP bought a new position in Senseonics Holdings during the second quarter valued at approximately $2,026,000. Finally, State Street Corp bought a new position in Senseonics Holdings during the second quarter valued at approximately $1,185,000.

About Senseonics Holdings

Senseonics Holdings, Inc, formerly ASN Technologies, Inc, is a medical technology company. The Company is focused on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed to be an implantable CGM system to continually measure glucose levels in people with diabetes for a period of approximately 90 days.

Get a free copy of the Zacks research report on Senseonics Holdings (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test


 
© 2006-2016 Ticker Report. Google+.